Regeneron Pharmaceuticals Extends Deal to Provide Ebola Treatment to US Government for $270 Million

08:01 AM EDT, 10/26/2026 (MT Newswires) -- Regeneron Pharmaceuticals (REGN) has extended its agreement with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority to provide additional supply of Inmazeb for preparedness against Ebola, the company said Monday. Under the new agreement, Regeneron plans to deliver additional treatment doses of Inmazeb treatment to the US government through 2031 for around $270 million. In a clinical trial, Inmazeb reduced Ebola mortality by around 55% compared to an active control treatment, the company said.